1 / 29

Chapter 50

Chapter 50. Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels. Prophylaxis of Coronary Heart Disease (CHD). Cholesterol Plasma lipoproteins Role of LDL cholesterol in atherosclerosis

ting
Download Presentation

Chapter 50

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chapter 50 Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels

  2. Prophylaxis of Coronary Heart Disease (CHD) • Cholesterol • Plasma lipoproteins • Role of LDL cholesterol in atherosclerosis • Detection, evaluation, and treatment of high cholesterol: recommendations from ATP III • Drugs and other products used to improve plasma lipid levels ATP = Adult Treatment Panel; LDL = low-density lipoprotein.

  3. Cholesterol • Component of all cell membranes and membranes of intracellular organelles • Required for synthesis of certain hormones and bile salts • Deposited in stratum corneum of the skin • Comes from dietary sources • Manufactured by cells, primarily in the liver • Increased dietary cholesterol produces only a small increase in cholesterol in the blood (inhibits endogenous cholesterol production)

  4. Plasma Lipoproteins • Structure and function of lipoproteins • Function • Basic structure • Apolipoproteins • Recognition sites for cell-surface receptors • Activate enzymes that metabolize lipoproteins • Increase the structural stability of lipoproteins

  5. Plasma Lipoproteins • Classes of lipoproteins • Six major classes of plasma lipoproteins • Three relevant to coronary atherosclerosis • Very-low-density lipoproteins (VLDLs) • Triglycerides • Low-density lipoproteins (LDLs) • Cholesterol primary core lipid • Greatest contributor to coronary heart disease (CHD) • High-density lipoproteins (HDLs) • Cholesterol

  6. Role of LDL Cholesterol in Atherosclerosis • LDLs initiate and fuel development of atherosclerosis • Process begins with transport of LDLs from the arterial lumen into endothelial cells, then into the space underlying the arterial epithelium

  7. Atherogenesis • More than just deposit of lipids • Now considered primarily a chronic inflammatory process • Infiltration of macrophages, T lymphocytes, and other inflammatory mediators

  8. Detection, Evaluation, and Treatment of High Cholesterol • Cholesterol screening • Every 5 years for adults over the age of 20 years • Total cholesterol • HDL cholesterol • Less than 40 mg/dL:low to undesirable • LDL cholesterol • Less than 100 mg/dL:desirable • Triglycerides (TGs)

  9. CHD Risk Assessment • Factors in risk assessment • Identifying CHD risk factors • Calculating 10-year CHD risk • Identifying CHD risk equivalents • Diabetes • Atherosclerotic disease other than CHD • Framingham risk score greater than 20% • Identifying an individual’s CHD risk category • Each type of dyslipidemia a patient has contributes independently to CHD risk

  10. Treatment of High-LDL Cholesterol • Therapeutic lifestyle changes (TLCs) • Smoking cessation • The TLC diet • Exercise

  11. Drug Therapy: Not First-Line Therapy • Drugs should be used only if TLCs fail • HMG-CoA reductase inhibitors • Bile-acid sequestrants • Nicotinic acid (niacin) • Fibrates (reduce levels of TGs, not LDLs) HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A.

  12. Secondary Treatment Targets • Metabolic syndrome • High blood glucose • High triglycerides • High apolipoprotein B • Low high-density lipoprotein (HDL) • Small LDL particles • Prothrombotic state • Proinflammatory state • Hypertension • High triglycerides • Levels above 150 mg/dL

  13. Treatment Goals for Metabolic Syndrome • Reduce the risk for atherosclerotic disease • Reduce the risk for type 2 diabetes • Increase physical activity

  14. Drugs and Other Products to Alter Plasma Lipid Levels • High LDL: contributes most to cardiovascular disease • Also consider • High total cholesterol • Low HDL cholesterol • High triglycerides • Drugs can improve lipid profiles, but not all improve clinical outcomes

  15. HMG-CoA Reductase Inhibitors (Statins) • Most effective drugs for lowering LDL • Reduction of LDL cholesterol • Elevation of HDL cholesterol • Reduction of triglyceride levels • Nonlipid beneficial cardiovascular actions • Promote plaque stability • Reduce the risk for cardiovascular (CV) events • Increased bone formation

  16. HMG-CoA Reductase Inhibitors (Statins) • Mechanism of cholesterol reduction • Clinical trials • Therapeutic uses • Hypercholesterolemia • Primary and secondary prevention of CV events • Post-MI therapy • Diabetes • Potential uses

  17. HMG-CoA Reductase Inhibitors (Statins) • Adverse effects • Common • Headache • Rash • GI disturbances • Rare • Myopathy/rhabdomyolysis • Hepatotoxicity

  18. HMG-CoA Reductase Inhibitor (Statins) • Drug interactions • Most other lipid-lowering drugs (except bile acid sequestrants) • Drugs that inhibit CYP3A4 • Use in pregnancy • Dosing should be once daily in the evening • Endogenous cholesterol synthesis increases during the night • Statins have greatest impact when given in the evening

  19. Nicotinic Acid (Niacin) • Reduces LDL and TG levels • Increases HDL levels more effectively than any other drug • Effect on plasma lipoproteins • Lowering TG levels • Raising HDL cholesterol

  20. Nicotinic Acid (Niacin) • Adverse effects • Skin (flushing, itching) • Intense flushing initially; can pretreat with aspirin • Decreased with SR version of niacin • Gastrointestinal • Hepatotoxicity • Hyperglycemia • Gouty arthritis • Can raise blood levels of uric acid

  21. Bile-Acid Sequestrants • Previously were first-line drugs • Now primarily used as adjuncts to statins • Cholestyramine • Colestipol • Colesevelam • Newest and better-tolerated drug • Does not decrease uptake of fat-soluble vitamins (as other bile sequestrants do) • Does not significantly reduce the absorption of statins, warfarin, digoxin, and most other drugs studied

  22. Bile-Acid Sequestrants • Colesevelam (cont’d) • Reduction in LDL cholesterol • Increased VLDL levels in some patients • Mechanism of action • Increases LDL receptors on hepatocytes • Prevents reabsorption of bile acids • Therapeutic use • Reduces LDL cholesterol (in conjunction with modified diet and exercise) • Adverse effects • Constipation

  23. Ezetimibe • Mechanism of action and impact on plasma lipids • Inhibits cholesterol absorption • Therapeutic use • Reduces total cholesterol, LDL cholesterol, and apolipoprotein B • Approved for monotherapy and combined use with statins

  24. Ezetimibe • Adverse effects • Myopathy • Rhabdomyolysis • Hepatitis • Pancreatitis • Thrombocytopenia • Drug interactions • Statins • Fibrates • Bile-acid sequestrants • Cyclosporine

  25. Fibric Acid Derivatives (Fibrates) • Most effective drugs available for lowering TG levels • Can raise HDL cholesterol • Little or no effect on LDL cholesterol • Can increase the risk for bleeding in patients on warfarin • Can increase the risk for rhabdomyolysis in patients taking statins • Three drugs in the United States • Gemfibrozil (Lopid) • Fenofibrate (Tricor, others) • Fenofibric acid (TriLipix)

  26. Gemfibrozil • Effects on plasma lipoproteins • Decreases plasma TG content • Lowers VLDL levels • Can raise HDL cholesterol • Mechanism • Appears to interact with a specific receptor subtype (PPAR alpha) • Drug interactions • Displaces warfarin from plasma albumin • Measure INR frequently

  27. Gemfibrozil • Therapeutic uses • Reduces high levels of plasma triglycerides (VLDLs) • Treatment reserved for patients who have not responded to diet modification • Less effective than statins in reducing LDL • Can raise HDL (not approved for this use) • Adverse effects • Rashes • Gastrointestinal disturbances • Gallstones • Myopathy • Liver injury (hepatotoxic)

  28. Other Products Used to Alter Plasma Lipid Levels • Fenofibrate • Fenofibric acid • Drug combinations • Niacin/lovastatin • Simvastatin/niacin, simvastatin/ezetimibe • Pravastatin/aspirin • Atorvastatin/amlodipine

  29. Other Products Used to Alter Plasma Lipid Levels • Lovaza • Fish oil • Plant stanol and sterol esters • Estrogen • Cholestin

More Related